China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with US-based DNA solutions provider Synbio Technologies. The collaboration aims to integrate resources across the cell and gene therapy (CGT) industry chain, thereby strengthening the development of the CGT industry in China.
Porton Biologics’ Comprehensive CGT CDMO Service Platform
Porton Biologics boasts an end-to-end CGT CDMO service platform that encompasses a wide range of therapies, including plasmids, cell therapies, gene therapies, oncolytic viruses, nucleic acid therapies, and live bacterial therapies. This comprehensive platform positions Porton as a key player in the CGT sector, capable of providing comprehensive services from development to manufacturing.
Synbio Technologies’ Synthetic Biology Expertise
Synbio Technologies, with a focus on synthetic biology, offers a broad spectrum of services covering codon optimization, sequence optimization, vector and antibody design, complex gene synthesis, vector construction, protein and cell engineering, and strain and cell development. Synbio’s expertise spans various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuels, and more.
Global Operations and Capabilities
Operating out of both China and the US, Synbio provides a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities. This partnership with Porton Biologics is expected to leverage Synbio’s advanced technologies and Porton’s end-to-end services to enhance the development and manufacturing of CGT products in China, further solidifying the country’s position in the global CGT industry.-Fineline Info & Tech
